MGNX
MacroGenics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.40
+3.53%Aug 13, 2026, 20:05 UTC
MacroGenics, Inc. reported its financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress.
Source:Aug 11, 2026, 20:05 UTC
Gilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.
Source:Jul 2, 2026, 13:25 UTC
MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals.
Source: